Treatment of malignant melanoma by downregulation of XIAP and overexpression of trail with a conditionally replicating oncolytic adenovirus

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 4, 2012, Pages 1471-1476

  Li, Xin Qiu ^a   Ke, Xian Zhu ^a   Wang, Yu Ming ^a  

^a HUBEI UNIVERSITY OF MEDICINE   (China)

Author keywords

Conditionally replicating oncolytic adenovirus; Malignant melanoma; Related apoptosis inducing ligand; TNF

Indexed keywords

CASPASE 3; CASPASE 8; ONCOLYTIC VIRUS; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; X LINKED INHIBITOR OF APOPTOSIS; XIAP PROTEIN, HUMAN;

ADENOVIRUS; ANALYSIS OF VARIANCE; ANIMAL; APOPTOSIS; ARTICLE; CANCER TRANSPLANTATION; CELL PROLIFERATION; CELL SURVIVAL; DOWN REGULATION; EXPERIMENTAL MELANOMA; GENE THERAPY; GENE VECTOR; GENETICS; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; SKIN TUMOR; TUMOR CELL LINE; UPREGULATION;

ADENOVIRIDAE; ANALYSIS OF VARIANCE; ANIMALS; APOPTOSIS; CASPASE 3; CASPASE 8; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; GENETIC THERAPY; GENETIC VECTORS; MELANOMA, EXPERIMENTAL; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; ONCOLYTIC VIRUSES; SKIN NEOPLASMS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; UP-REGULATION; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84873030519     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.4.1471     Document Type: Article

References (46)

1. Addison CL, Bramson JL, Hitt MM, et al (1998). Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors. Gene Ther, 5, 1400-9.
2. Alemany R (2007). Cancer selective adenoviruses. Mol Aspects Med, 28, 42-58.
3. Anderson RD, Haskell RE, Xia H, et al (2000). A simple method for the rapid generation of recombinant adenovirus vectors. Gene Ther, 7, 1034-8.
4. Bellew S, Del Rosso JQ, Kim GK (2009). Skin cancer in asians: part 2: melanoma. J Clin Aesthet Dermatol, 2, 34-6.
5. Bischoff JR, Kirn DH, Williams A, et al (1996). An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science, 274, 373-6.
6. Debatin KM (1997). Cytotoxic drugs, programmed cell death, and the immune system: defining new roles in an old play. J Natl Cancer Inst, 89, 750-1.
7. Douglas JT (2007). Adenoviral vectors for gene therapy. Mol Biotechnol, 36, 71-80.
8. El-Serag HB, Rudolph KL (2007). Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 132, 2557-76.
9. Ghosh SS, Gopinath P, Ramesh A (2006). Adenoviral vectors: a promising tool for gene therapy. Appl Biochem Biotechnol, 133, 9-29.
10. Gross A, McDonnell JM, Korsmeyer SJ (1999). BCL-2 family members and the mitochondria in apoptosis. Genes Dev, 13, 1899-911.
11. Hall MA, Cleveland JL (2007). Clearing the TRAIL for Cancer Therapy. Cancer Cell, 12, 4-6.
12. Harlin H, Reffey SB, Duckett CS, et al (2001). Characterization of XIAP-deficient mice. Mol Cell Biol, 21, 3604-8.
13. Haviv YS (2009). A simplified in vitro ligation approach to clone an E1B55k-deleted double-targeted conditionally-replicative adenovirus. Virol J, 6, 18.
14. Heise C, Sampson-Johannes A, Williams A, et al (1997). ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med, 3, 639-45.
15. Hermiston TW, Kuhn I (2002). Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes. Cancer Gene Ther, 9, 1022-35.
16. Holcik M, Korneluk RG (2001). XIAP, the guardian angel. Nat Rev Mol Cell Biol, 2, 550-6.
17. Holcik M, Yeh C, Korneluk RG, et al (2000). Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell death. Oncogene, 19, 4174-7.
18. Holoch PA, Griffith TS (2009). TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Eur J Pharmacol, 625, 63-72.
19. Huang X, Lin T, Gu J, et al (2002). Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer xenograft. Gene Ther, 9, 1379-86.
20. Huang Y, Sheikh MS (2007). TRAIL death receptors and cancer therapeutics. Toxicol Appl Pharmacol, 224, 284-9.
21. Huerta-Yepez S, Vega M, Jazirehi A, et al (2004). Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression. Oncogene, 23, 4993-5003.
22. Hunter AM, LaCasse EC, Korneluk RG (2007). The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis, 12, 1543-68.
23. Jiang H, Conrad C, Fueyo J, et al (2003). Oncolytic adenoviruses for malignant glioma therapy. Front Biosci, 8, d577-88.
24. Kaufmann SH and Earnshaw WC (2000). Induction of apoptosis by cancer chemotherapy. Exp Cell Res, 256, 42-49.
25. Khuri FR, Nemunaitis J, Ganly I, et al (2000). a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med, 6, 879-885.
26. Kirn D, Martuza RL, Zwiebel J (2001). Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med, 7, 781-7.
27. Mahalingam D, Oldenhuis CN, Szegezdi E, et al (2011). Targeting trail towards the clinic. Curr Drug Targets, 12, 2079-90.
28. McManus DC, Lefebvre CA, Cherton-Horvat G, et al (2004). Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene, 23, 8105-17.
29. Mitry RR, Mansour MR, Havlik R, et al (2000). Gene therapy for liver tumours. Adv Exp Med Biol, 465, 193-205.
30. Opyrchal M, Aderca I, Galanis E (2009). Phase I clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas. Methods Mol Biol, 542, 705-17.
31. Rosato RR, Dai Y, Almenara JA, et al (2004). Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation. Leukemia, 18, 1780-8.
32. Ruiz J, Qian C, Drozdzik M, et al (1999). Gene therapy of viral hepatitis and hepatocellular carcinoma. J Viral Hepat, 6, 17-34.
33. Sharma A, Tandon M, Bangari DS, et al (2009). Adenoviral vector-based strategies for cancer therapy. Curr Drug Ther, 4, 117-38.
34. Shi RX, Ong CN, Shen HM (2005). Protein kinase C inhibition and x-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells. Cancer Res, 65, 7815-23.
35. Short JJ, Curiel DT (2009). Oncolytic adenoviruses targeted to cancer stem cells. Mol Cancer Ther, 8, 2096-102.
36. Suliman A, Lam A, Datta R, et al (2001). Intracellular mechanisms of TRAIL: apoptosis through mitochondrialdependent and -independent pathways. Oncogene, 20, 2122-33.
37. Verma IM, Somia N (1997). Gene therapy-promises, problems and prospects. Nature, 389, 239-42.
38. Volpers C, Kochanek S (2004). Adenoviral vectors for gene transfer and therapy. J Gene Med, 6, S164-71.
39. von Haefen C, Gillissen B, Hemmati PG, et al (2004). Multidomain Bcl-2 homolog Bax but not Bak mediates synergistic induction of apoptosis by TRAIL and 5-FU through the mitochondrial apoptosis pathway. Oncogene, 23, 8320-32.
40. Walczak H, Krammer PH (2000). The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res, 256, 58-66.
41. Walczak H, Miller RE, Ariail K, et al (1999). Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med, 5, 157-63.
42. Wang S (2010). TRAIL: a sword for killing tumors. Curr Med Chem, 17, 3309-17.
43. Wang S, El-Deiry WS (2003). TRAIL and apoptosis induction by TNF-family death receptors. Oncogene, 22, 8628-33.
44. Zhang S, Shen HM and Ong CN (2005). Down-regulation of c-FLIP contributes to the sensitization effect of 3, 3'-diindolylmethane on TRAIL-induced apoptosis in cancer cells. Mol Cancer Ther, 4, 1972-81.
45. Zhao L, Dong A, Gu J, et al (2006). The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer. Cancer Gene Ther, 13, 1011-22.
46. Zhu ZB, Lu B, Park M, et al (2008). Development of an optimized conditionally replicative adenoviral agent for ovarian cancer. Int J Oncol, 32, 1179-88.